Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015261 | 0.76 | OPRL1 (0.46) | OPRL1POLBCHRM2CCR3ALDH1A1 | |
| SCHEMBL5016405 | 0.74 | AKT1 (0.61) | DRD4SMODRD2AKT1AKT2 | |
| SCHEMBL2008062 | 0.70 | KMT2A (0.47) | DRD4CHRM2DRD2DRD3ALDH1A1 | |
| SCHEMBL3905400 | 0.70 | OPRL1 (0.63) | OPRL1POLBCHRM2CCR3ALDH1A1 | |
| SCHEMBL3212649 | 0.69 | OPRL1 (0.58) | OPRL1POLBCHRM2CCR3AKT1 | |
| Hydrochloric Acid SCHEMBL7751618 | 0.69 | POLB (0.64) | OPRL1POLBCHRM2CCR3ALDH1A1 | |
| SCHEMBL2518972 | 0.69 | OPRL1 (0.59) | OPRL1POLBCHRM2CCR3DRD2 | |
| SCHEMBL7866429 | 0.69 | OPRL1 (0.57) | OPRL1POLBCHRM2CCR3ALDH1A1 | |
| SCHEMBL8891476 | 0.68 | CCR3 (0.89) | OPRL1POLBDRD4CCR3DRD2 | |
| SCHEMBL11626032 | 0.68 | OPRL1 (0.56) | OPRL1POLBDRD4CHRM2CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1250337-B1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-03 | — | — | EP | disclosed |
| US-7304052-B2 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUITCA N.V. (BE) | 2007-12-04 | — | — | US | disclosed |
| US-20030139393-A1 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-24 | — | — | US | disclosed |
| EP-1250337-A1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | Janssen Pharmaceutica N.V. (BE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001046189-A1 | SUBSTITUTED HOMOPIPERIDINYL BENZIMIDAZOLE ANALOGUES AS FUNDIC RELAXANTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139393-A1 | Substituted homopiperidinyl benzimidazole analogues as fundic relaxants | HRH2, CBR1, HTR1D | OPRL1 152/4885POLB 3374/4885DRD4 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.